233 related articles for article (PubMed ID: 35721612)
1. Novel Keap1-Nrf2 Protein-Protein Interaction Inhibitor UBE-1099 Ameliorates Progressive Phenotype in Alport Syndrome Mouse Model.
Kaseda S; Sannomiya Y; Horizono J; Kuwazuru J; Suico MA; Ogi S; Sasaki R; Sunamoto H; Fukiya H; Nishiyama H; Kamura M; Niinou S; Koyama Y; Nara F; Shuto T; Onuma K; Kai H
Kidney360; 2022 Apr; 3(4):687-699. PubMed ID: 35721612
[TBL] [Abstract][Full Text] [Related]
2. Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
Nezu M; Suzuki N; Yamamoto M
Am J Nephrol; 2017; 45(6):473-483. PubMed ID: 28502971
[TBL] [Abstract][Full Text] [Related]
3. Bardoxolone ameliorates TGF-β1-associated renal fibrosis through Nrf2/Smad7 elevation.
Song MK; Lee JH; Ryoo IG; Lee SH; Ku SK; Kwak MK
Free Radic Biol Med; 2019 Jul; 138():33-42. PubMed ID: 31059771
[TBL] [Abstract][Full Text] [Related]
4. ZJ01, a Small Molecule Inhibitor of the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction, Reduces Hyperoxic Acute Lung Injury in a Mouse Model.
Wan J; Lin S; Huang X; Li Q; Zeng L; Du S
Med Sci Monit; 2020 May; 26():e920467. PubMed ID: 32437336
[TBL] [Abstract][Full Text] [Related]
5. Keap1-Nrf2 signaling activation by Bardoxolone-methyl ameliorates high glucose-induced oxidative injury in human umbilical vein endothelial cells.
Yang JL; Sun MY; Yuan Q; Tang S; Dong MJ; Zhang RD; Liu YY; Mao L
Aging (Albany NY); 2020 Jun; 12(11):10370-10380. PubMed ID: 32484788
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent deleterious and salutary actions of the Nrf2 inducer dh404 in chronic kidney disease.
Vaziri ND; Liu S; Farzaneh SH; Nazertehrani S; Khazaeli M; Zhao YY
Free Radic Biol Med; 2015 Sep; 86():374-81. PubMed ID: 25930007
[TBL] [Abstract][Full Text] [Related]
7. Genetic or pharmacologic Nrf2 activation increases proteinuria in chronic kidney disease in mice.
Rush BM; Bondi CD; Stocker SD; Barry KM; Small SA; Ong J; Jobbagy S; Stolz DB; Bastacky SI; Chartoumpekis DV; Kensler TW; Tan RJ
Kidney Int; 2021 Jan; 99(1):102-116. PubMed ID: 32818518
[TBL] [Abstract][Full Text] [Related]
8. A Point Mutation at C151 of
Gatbonton-Schwager T; Yagishita Y; Joshi T; Wakabayashi N; Srinivasan H; Suzuki T; Yamamoto M; Kensler TW
Mol Pharmacol; 2023 Aug; 104(2):51-61. PubMed ID: 37188495
[TBL] [Abstract][Full Text] [Related]
9. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions.
Lu MC; Shao HL; Liu T; You QD; Jiang ZY
Eur J Med Chem; 2020 Dec; 207():112734. PubMed ID: 32866756
[TBL] [Abstract][Full Text] [Related]
11. Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway.
Wu J; Liu X; Fan J; Chen W; Wang J; Zeng Y; Feng X; Yu X; Yang X
Toxicology; 2014 Apr; 318():22-31. PubMed ID: 24530882
[TBL] [Abstract][Full Text] [Related]
12. CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-κB activation.
Lu MC; Zhao J; Liu YT; Liu T; Tao MM; You QD; Jiang ZY
Redox Biol; 2019 Sep; 26():101266. PubMed ID: 31279986
[TBL] [Abstract][Full Text] [Related]
13. Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model.
Kim S; Indu Viswanath AN; Park JH; Lee HE; Park AY; Choi JW; Kim HJ; Londhe AM; Jang BK; Lee J; Hwang H; Lim SM; Pae AN; Park KD
Neuropharmacology; 2020 May; 167():107989. PubMed ID: 32032607
[TBL] [Abstract][Full Text] [Related]
14. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.
Lu MC; Ji JA; Jiang ZY; You QD
Med Res Rev; 2016 Sep; 36(5):924-63. PubMed ID: 27192495
[TBL] [Abstract][Full Text] [Related]
15. Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.
Jiang ZY; Lu MC; You QD
J Med Chem; 2016 Dec; 59(24):10837-10858. PubMed ID: 27690435
[TBL] [Abstract][Full Text] [Related]
16. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
Pallesen JS; Tran KT; Bach A
J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
[TBL] [Abstract][Full Text] [Related]
17. Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor.
Yasuda D; Yuasa A; Obata R; Nakajima M; Takahashi K; Ohe T; Ichimura Y; Komatsu M; Yamamoto M; Imamura R; Kojima H; Okabe T; Nagano T; Mashino T
Bioorg Med Chem Lett; 2017 Nov; 27(22):5006-5009. PubMed ID: 29037947
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics of Chemically Distinct Classes of Keap1-Nrf2 Activators Identify Common and Unique Gene, Protein, and Pathway Responses In Vivo.
Wible RS; Tran QT; Fathima S; Sutter CH; Kensler TW; Sutter TR
Mol Pharmacol; 2018 Apr; 93(4):297-308. PubMed ID: 29367259
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Structure-Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.
Zhou HS; Hu LB; Zhang H; Shan WX; Wang Y; Li X; Liu T; Zhao J; You QD; Jiang ZY
J Med Chem; 2020 Oct; 63(19):11149-11168. PubMed ID: 32902980
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel small-molecule Keap1-Nrf2 PPI inhibitor with cytoprotective effects on LPS-induced cardiomyopathy.
Jiang CS; Zhuang CL; Zhu K; Zhang J; Muehlmann LA; Figueiró Longo JP; Azevedo RB; Zhang W; Meng N; Zhang H
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):833-841. PubMed ID: 29693453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
